Epoxide hydrolase
From Proteopedia
(Difference between revisions)
| Line 14: | Line 14: | ||
<scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref> | <scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref> | ||
| + | |||
| + | == 3D Structures of epoxide hydrolase== | ||
| + | [[Epoxide hydrolase 3D structures]] | ||
| + | |||
</StructureSection> | </StructureSection> | ||
| Line 27: | Line 31: | ||
**[[2cjp]] – pEH I – potato<br /> | **[[2cjp]] – pEH I – potato<br /> | ||
**[[3cxu]], [[4ufn]], [[4ufo]], [[4ufp]], [[4uhb]], [[4y9s]] – pEH (mutant) <br /> | **[[3cxu]], [[4ufn]], [[4ufo]], [[4ufp]], [[4uhb]], [[4y9s]] – pEH (mutant) <br /> | ||
| - | **[[4i19]], [[4qa9]], [[ | + | **[[4i19]], [[4qa9]], [[5f4z]] – EH – ''Streptomyces carzinostaticus''<br /> |
| + | **[[4qla]] – EH – silkworm<br /> | ||
| + | **[[5cxo]] – EH – ''Streptomyces albus''<br /> | ||
| + | **[[5nfq]], [[5ng7]] – EH – metagenome<br /> | ||
| + | **[[5xmd]] – mbEH – mung bean<br /> | ||
| + | **[[5y6y]], [[5y5d]], [[5xm6]] – mbEH (mutant)<br /> | ||
*Soluble epoxide hydrolase | *Soluble epoxide hydrolase | ||
**[[1s8o]], [[3i1y]], [[3i28]], [[3koo]], [[5ahx]], [[5fp0]] – hSEH – human<br /> | **[[1s8o]], [[3i1y]], [[3i28]], [[3koo]], [[5ahx]], [[5fp0]] – hSEH – human<br /> | ||
| + | **[[6i5e]] – hSEH C terminal<br /> | ||
**[[1cqz]] – mSEH – mouse<br /> | **[[1cqz]] – mSEH – mouse<br /> | ||
**[[4nzz]] – BmSEH – ''Bacillus megaterium''<br /> | **[[4nzz]] – BmSEH – ''Bacillus megaterium''<br /> | ||
| Line 42: | Line 52: | ||
**[[3rga]] – SlEH + oxazolidinone inhibitor – ''Streptomyces lasaliensis''<br /> | **[[3rga]] – SlEH + oxazolidinone inhibitor – ''Streptomyces lasaliensis''<br /> | ||
**[[4rzm]] – SlEH + lasalocid A<br /> | **[[4rzm]] – SlEH + lasalocid A<br /> | ||
| + | **[[5yb5]] – mbEH (mutant) + styrene derivative<br /> | ||
*Soluble epoxide hydrolase complex with inhibitor | *Soluble epoxide hydrolase complex with inhibitor | ||
| - | **[[1vj5]], [[1zd2]], [[1zd3]], [[1zd4]], [[1zd5]], [[3wk4]], [[4c4x]], [[4c4y]], [[4c4z]], [[5ai5]], [[5akz]], [[5ali]] – hSEH + urea derivative inhibitor<br /> | + | **[[1vj5]], [[1zd2]], [[1zd3]], [[1zd4]], [[1zd5]], [[3wk4]], [[4c4x]], [[4c4y]], [[4c4z]], [[5ai5]], [[5akz]], [[5ali]], [[6aum]], [[6fr2]] – hSEH + urea derivative inhibitor<br /> |
**[[1cr6]], [[1ek1]], [[1ek2]] – mSEH + urea derivative inhibitor<br /> | **[[1cr6]], [[1ek1]], [[1ek2]] – mSEH + urea derivative inhibitor<br /> | ||
**[[3otq]], [[3wk7]], [[4y2j]], [[4y2s]], [[4y2v]], [[5ak4]], [[5akh]], [[5aki]], [[5alk]], [[5alq]], [[5alv]], [[5aly]] – hSEH + pyrazole inhibitor<br /> | **[[3otq]], [[3wk7]], [[4y2j]], [[4y2s]], [[4y2v]], [[5ak4]], [[5akh]], [[5aki]], [[5alk]], [[5alq]], [[5alv]], [[5aly]] – hSEH + pyrazole inhibitor<br /> | ||
| Line 70: | Line 81: | ||
**[[5ai0]] – hSEH + phenyl oxadiazolamine inhibitor<br /> | **[[5ai0]] – hSEH + phenyl oxadiazolamine inhibitor<br /> | ||
**[[5ai9]] – hSEH + phenol derivative inhibitor<br /> | **[[5ai9]] – hSEH + phenol derivative inhibitor<br /> | ||
| - | **[[5aia]] – hSEH + benzoate derivative inhibitor<br /> | + | **[[5aia]], [[5mwa]] – hSEH + benzoate derivative inhibitor<br /> |
**[[5ak3]] – hSEH + indan-amine derivative inhibitor<br /> | **[[5ak3]] – hSEH + indan-amine derivative inhibitor<br /> | ||
**[[5all]] – hSEH + cyclohexyl methanol inhibitor<br /> | **[[5all]] – hSEH + cyclohexyl methanol inhibitor<br /> | ||
| + | **[[6i5g]] – hSEH C terminal + prostaglandin derivative<br /> | ||
**[[4o08]] – BmSEH + phenoxy acetamide inhibitor<br /> | **[[4o08]] – BmSEH + phenoxy acetamide inhibitor<br /> | ||
| Line 82: | Line 94: | ||
**[[1nww]] – ReEH – ''Rhodococcus erythropolis''<br /> | **[[1nww]] – ReEH – ''Rhodococcus erythropolis''<br /> | ||
| - | **[[4r9k]], [[4r9l]], [[4xbx]], [[4xdw]], [[5cf1]], [[5cf2]], [[5jpp]] – ReEH (mutant)<br /> | + | **[[4r9k]], [[4r9l]], [[4xbx]], [[4xdw]], [[5cf1]], [[5cf2]], [[5jpp]], [[5gkw]] – ReEH (mutant)<br /> |
**[[1nu3]] – ReEH + valpromide <br /> | **[[1nu3]] – ReEH + valpromide <br /> | ||
| - | **[[4xbt]], [[4xdv]], [[5clk]], [[5jpu]] – ReEH (mutant) + | + | **[[4xbt]], [[4xdv]], [[5clk]], [[5jpu]], [[5yao]] – ReEH (mutant) + hexane derivative<br /> |
| - | **[[4xby]], [[5ck6]] – ReEH (mutant) + cyclopentene oxide<br /> | + | **[[4xby]], [[5ck6]], [[5yng]], [[5yqt]] – ReEH (mutant) + cyclopentene oxide<br /> |
**[[5aif]], [[5aih]], [[5aii]] – mlEH – metagenomic library<br /> | **[[5aif]], [[5aih]], [[5aii]] – mlEH – metagenomic library<br /> | ||
**[[5aig]] – mlEH + valpromide <br /> | **[[5aig]] – mlEH + valpromide <br /> | ||
Revision as of 09:10, 23 June 2019
| |||||||||||
3D Structures of epoxide hydrolase
Updated on 23-June-2019
References
- ↑ Biswal BK, Morisseau C, Garen G, Cherney MM, Garen C, Niu C, Hammock BD, James MN. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. J Mol Biol. 2008 Sep 12;381(4):897-912. Epub 2008 Jun 17. PMID:18585390 doi:10.1016/j.jmb.2008.06.030
- ↑ Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ, de Bont JA, Jones TA, Mowbray SL. Structure of Rhodococcus erythropolis limonene-1,2-epoxide hydrolase reveals a novel active site. EMBO J. 2003 Jun 2;22(11):2583-92. PMID:12773375 doi:http://dx.doi.org/10.1093/emboj/cdg275
- ↑ Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875. PMID:19794443 doi:http://dx.doi.org/10.1038/nrd2875
- ↑ Oster L, Tapani S, Xue Y, Kack H. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today. 2015 Apr 28. pii: S1359-6446(15)00154-3. doi:, 10.1016/j.drudis.2015.04.005. PMID:25931264 doi:http://dx.doi.org/10.1016/j.drudis.2015.04.005
